Matches in Wikidata for { <http://www.wikidata.org/entity/Q37842928> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- Q37842928 description "article científic" @default.
- Q37842928 description "article scientifique" @default.
- Q37842928 description "articolo scientifico" @default.
- Q37842928 description "artigo científico" @default.
- Q37842928 description "artículu científicu espublizáu en 2011" @default.
- Q37842928 description "bilimsel makale" @default.
- Q37842928 description "scientific article published on 31 January 2011" @default.
- Q37842928 description "vedecký článok" @default.
- Q37842928 description "vetenskaplig artikel" @default.
- Q37842928 description "videnskabelig artikel" @default.
- Q37842928 description "vědecký článek" @default.
- Q37842928 description "wetenschappelijk artikel" @default.
- Q37842928 description "wissenschaftlicher Artikel" @default.
- Q37842928 description "наукова стаття, опублікована в січні 2011" @default.
- Q37842928 description "научни чланак" @default.
- Q37842928 description "مقالة علمية نشرت في 31 يناير 2011" @default.
- Q37842928 name "Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility" @default.
- Q37842928 name "Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility" @default.
- Q37842928 name "Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility" @default.
- Q37842928 type Item @default.
- Q37842928 label "Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility" @default.
- Q37842928 label "Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility" @default.
- Q37842928 label "Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility" @default.
- Q37842928 prefLabel "Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility" @default.
- Q37842928 prefLabel "Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility" @default.
- Q37842928 prefLabel "Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility" @default.
- Q37842928 P1433 Q37842928-97026630-823F-4F99-B5F0-8869AF5BA6CF @default.
- Q37842928 P1476 Q37842928-2FD447C7-45B5-4369-B434-4695E3805E62 @default.
- Q37842928 P2093 Q37842928-0536F3AD-BA81-4858-81B4-ECCE4BB10906 @default.
- Q37842928 P2093 Q37842928-0DC46625-41EE-45B6-B1AC-B02EAADBDB55 @default.
- Q37842928 P2093 Q37842928-19638423-D3CC-45EC-8D93-70776F04B30C @default.
- Q37842928 P2093 Q37842928-2A56E6C2-744A-44E8-9B3C-346D70A68A67 @default.
- Q37842928 P2093 Q37842928-2C82A765-FEAD-4EB0-9456-2E5B214DC65F @default.
- Q37842928 P2093 Q37842928-37967AC8-AB91-439B-83D3-6A93625800BC @default.
- Q37842928 P2093 Q37842928-41AB7838-84C1-49AD-9C97-315BC26230F4 @default.
- Q37842928 P2093 Q37842928-51B0D318-B6A8-4BD3-AB0D-FA8A05A7CF7D @default.
- Q37842928 P2093 Q37842928-6C65D590-53D0-49B7-B1DA-F55B83E061DF @default.
- Q37842928 P2093 Q37842928-74D4F626-E9A3-4492-ACC8-A3DF91BB52CF @default.
- Q37842928 P2093 Q37842928-83116001-13BA-4DB1-8B1B-8372A27010FA @default.
- Q37842928 P2093 Q37842928-8BF5A9C2-6D25-4B6B-B726-343DD19A5A0B @default.
- Q37842928 P2093 Q37842928-D440E61A-599C-4731-A795-95032DF97FB0 @default.
- Q37842928 P2093 Q37842928-D66095F4-677C-49FE-99D5-E48C5D8A08AE @default.
- Q37842928 P304 Q37842928-498E44E0-3622-4BBC-B250-7E2C3C94A2D5 @default.
- Q37842928 P31 Q37842928-C9D3441A-83C6-4238-B387-03EE482D3E58 @default.
- Q37842928 P356 Q37842928-92017C10-D020-4643-9F2E-2DA68F31DFF4 @default.
- Q37842928 P407 Q37842928-DDE4472D-62F6-4C46-862C-CC73B7A5970B @default.
- Q37842928 P433 Q37842928-66B70056-B3A0-401C-8F14-AB63CBE7AAA4 @default.
- Q37842928 P478 Q37842928-C2C0FC31-A28F-41D3-A4CF-84D1E7C6AAB9 @default.
- Q37842928 P577 Q37842928-93F9CE2A-A370-44F0-A0F6-E6B9E2121A24 @default.
- Q37842928 P698 Q37842928-824EE5CC-DCBA-4018-913B-57E3374C2EA0 @default.
- Q37842928 P356 J.BMCL.2011.01.111 @default.
- Q37842928 P698 21324686 @default.
- Q37842928 P1433 Q2709483 @default.
- Q37842928 P1476 "Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility" @default.
- Q37842928 P2093 "Boris M Seletsky" @default.
- Q37842928 P2093 "Bruce A Littlefield" @default.
- Q37842928 P2093 "Bryan M Lewis" @default.
- Q37842928 P2093 "Eric M Carlson" @default.
- Q37842928 P2093 "Hong Du" @default.
- Q37842928 P2093 "Hongsheng Cheng" @default.
- Q37842928 P2093 "Huiming Zhang" @default.
- Q37842928 P2093 "Karen Tendyke" @default.
- Q37842928 P2093 "Melvin J Yu" @default.
- Q37842928 P2093 "Murray J Towle" @default.
- Q37842928 P2093 "Sridhar Narayan" @default.
- Q37842928 P2093 "Wanjun Zheng" @default.
- Q37842928 P2093 "Yimin Jiang" @default.
- Q37842928 P2093 "Yongbo Hu" @default.
- Q37842928 P304 "1630-1633" @default.
- Q37842928 P31 Q13442814 @default.
- Q37842928 P356 "10.1016/J.BMCL.2011.01.111" @default.
- Q37842928 P407 Q1860 @default.
- Q37842928 P433 "6" @default.
- Q37842928 P478 "21" @default.
- Q37842928 P577 "2011-01-31T00:00:00Z" @default.
- Q37842928 P698 "21324686" @default.